News >

FDA Grants Priority Review to Selinexor for Relapsed/Refractory DLBCL

Gina Columbus @ginacolumbusonc
Published: Wednesday, Feb 19, 2020

Sharon Shacham, PhD, MBA, founder, president and chief scientific officer of Karyopharm

Sharon Shacham, PhD, MBA

The FDA has granted a priority review designation to a supplemental new drug application (sNDA) for selinexor (Xpovio) as a treatment for adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, who have received ≥2 prior therapies.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication